A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing LOXO-292 to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531) (NCT04211337)
LIBRETTO-531
This trial is No longer recruiting
Registration number NCT04211337
Program & service
This trial is being run with the Specialty Medicine service, and as part of the Endocrine & Diabetes program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Professor Duncan Topliss
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR